Daniel Curcio holds an M.D. degree. He works as an Infectious Diseases Coordinator. He works in clinical trials since 2001 as a principal investigator (e.g., skin and soft tissue infections, intra-abdominal infections, and nosocomial pneumonia) and coinvestigator (e.g., community acquired pneumonia). He has more than 45 international publications related to the antibiotic use in hospitalized patients. He is also Reviewer for several journals, including Lancet Infectious Diseases, Journal of Antimicrobial Chemotherapy, Journal of Chemotherapy, International Journal of Infectious Diseases, Journal of Infection, European Infectious Diseases, Expert Review of Anti-infective Therapy, Annals of Medical and Health Sciences Research, Recent Patents on Anti-Infective Drug Discovery, and Current Clinical Pharmacology. Curcio was Speaker/Adviser of several pharmaceuticals companies (Bristol Myers Squibb, Bagó Argentina, among others). He is a Member of the Advisory Board of Tygacil™ and Prevnar 13 (Pfizer, formerly Wyeth Pharmaceuticals), the Antimicrobial Practices and Executions for Excellence (APEX), and the Latin American Antibiotic Use in Intensive Care Unit Group (ATB-ICU). Curcio has dictated during 2009–2012 more than 45 conferences in Latin America and 35 in the rest of the world, including Europe, North America, Middle East, and Asia Pacific. His specialties include internal medicine, infectious diseases, and clinical bacteriology.
Biography Updated on 6 January 2013